Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Phase of Trial: Phase II/III
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 03 Apr 2018 Status changed from recruiting to completed.
- 03 May 2017 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.